(77 days)
Knockout™ SR Medium and Knockout™ SR Xenofree Medium are liquid tissue culture medium products intended for human ex vivo tissue and cell culture processing applications.
Knockout™ SR is a serum-free medium with a defined formulation that provides consistent growth conditions for human and mouse embryonic stem cell (ESC) and patient-specific induced pluripotent cell lines (iPSCs).
Knockout™ SR Xenofree is a serum-free and animal origin-free defined formulation that provides consistent growth conditions for human and mouse embryonic stem cell (ESC) and patient-specific induced pluripotent cell lines (iPSCs). All animal derived components have been replaced with human derived or synthetic components to yield a xenogeneic-free formulation.
The provided document describes the acceptance criteria and the study that demonstrates the performance of Knockout™ SR Medium and Knockout™ SR Xenofree Medium, which are tissue culture media. This is not a medical device in the typical sense of a diagnostic or therapeutic AI-powered tool. Therefore, many of the requested categories for AI-based device performance studies (like MRMC studies, number of experts for ground truth, sample size of test/training sets, adjudication methods, and standalone performance metrics of an algorithm) are not applicable to this type of product.
However, I can extract the relevant performance criteria and how the manufacturer demonstrates compliance.
1. Table of Acceptance Criteria and Reported Device Performance
| Special Control Objective (Acceptance Criteria) | Life Technologies Corporation Knockout™ SR Medium Performance |
|---|---|
| Demonstrate lack of potential toxicity of materials in the media to cells or tissue and demonstrate support of tissue and cell growth | ES Cell Morphology: Demonstrated through specific morphology observed. Relative Plate Efficiency: Demonstrated as comparable to predicate. Relative Type 1 Colonies: Demonstrated as comparable to predicate. Also, noted that ES and iPSC grown in Knockout™ SR supplemented media are "substantially less differentiated than those grown in fetal bovine serum (FBS) supplemented media." For stability testing, it was demonstrated that the media was not cytotoxic and supported the growth of mammalian cells throughout its shelf life. |
| Demonstrate lack of endotoxin or pyrogen contamination | Limulus Ameobocyte (LAL) test (25 USP Monograph <85>) was performed and met acceptance criteria. |
| Validation of Aseptic Processing and Sterility Assurance Level (SAL) | Determination of SAL to be ≥ 10⁻³ compliance with GMP requirements regarding aseptic processing. |
| Demonstrates Chemical purity | Incoming Raw Material testing using USP, ACS, FCC, GIBCO, or Cell Culture requirements. |
| Stability/Shelf Life | Established a shelf life of 14-months when stored between 2°C-8°C. This was demonstrated by assessing: 1. pH continued to meet specifications. 2. Media was not cytotoxic and supported the growth of mammalian cells. 3. Container/closure integrity testing confirmed protection from microbial contamination. |
2. Sample Size Used for the Test Set and Data Provenance
This is not applicable as the studies described are laboratory-based assays and stability tests for a cell culture medium, not clinical studies with patient data. The "test set" would refer to internal lab samples and batches of the media.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
Not applicable. The "ground truth" for chemical purity, sterility, and cell growth support is established through standardized laboratory assays and protocols, not by expert human review in the context of radiology or pathology, for example.
4. Adjudication Method for the Test Set
Not applicable. Laboratory test results are typically objective measurements against predefined specifications, not subjective assessments requiring adjudication.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, If So, What Was the Effect Size of How Much Human Readers Improve with AI vs Without AI Assistance
Not applicable. This device is not an AI-powered diagnostic or therapeutic tool for human readers.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Not applicable. This device is a cell culture medium, not an algorithm.
7. The Type of Ground Truth Used
The ground truth is based on:
- Established laboratory assay specifications: For LAL test (<85> USP Monograph), SAL determination (≥ 10⁻³), and incoming raw material testing (USP, ACS, FCC, GIBCO, or Cell Culture requirements).
- Scientific and biological principles: For ES cell morphology, relative plate efficiency, and relative type 1 colonies, indicating proper cell growth and differentiation status.
- Physical and chemical specifications: For pH and container integrity over time.
8. The Sample Size for the Training Set
Not applicable. This is not a machine learning or AI model that requires a training set. The development of the media involved formulation and optimization, but not in the sense of an algorithm training on data.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set in the context of an AI device. The "ground truth" for the medium's development would have been empirically determined optimal conditions for cell culture based on literature, prior research, and internal experiments to achieve desired cell growth and maintenance characteristics. The company mentions a long history and substantial literature (300+ references) for Knockout™ SR, suggesting a robust scientific foundation for its formulation.
{0}------------------------------------------------
K100616
163
510 (k) Summary
MAY 2 0 2010
Life Technologies Corporation - Knockout™ SR Medium and Knockout™ SR Xenofree Medium
| Device Name: | KnockoutTM SR MediumKnockoutTM SR Xenofree Medium |
|---|---|
| Common/Usual Name: | KSRKSR Xenofree |
| Classification Name: | Tissue culture media for human ex vivo tissue and cellculture processing applications (per 21 CFR § 876.5885 |
| Product Code: | NDS |
| Submitter: | Life Technologies Corporation3175 Staley RoadGrand Island, New York 14072 |
| Telephone: | (716) 774-3122 |
| Facsimile: | (716) 774-0230 |
| Email: | kelli.tanzella@lifetech.com |
| Contact: | Kelli Tanzella, Ph.D. |
| Date Prepared: | March 01, 2010 |
| Trade Name | Manufacturer | 510(k) |
|---|---|---|
| AIM-V® Medium | Life Technologies Corporation(formerly Invitrogen Corporation) | K022080 |
Intended Use
Knockout™ SR Medium and Knockout™ SR Xenofree Medium are liquid tissue culture media product intended for human ex vivo tissue and cell culture processing applications.
Substantial Equivalence
AIM-V® Medium is the predicate device for tissue culture media intended for human ex vivo tissue and cell culture processing applications. It is composed of chemically defined nutrient materials in solution (with or without supplements) that are essential for the survival and development of tissue or cells of human or other animal origin. These nutrients are provided in liguid form for use in supporting the growth or maintenance of human tissue and cells.
{1}------------------------------------------------
Page 2 510(k) Summary - Life Technologies Knockout™ SR Medium and Knockout™ SR Xenofree Medium
A. Intended Uses
Knockout™ SR Medium and Knockout™ SR Xenofree Medium and AIM-V® Medium tissue culture products are intended for human ex vivo tissue and cell culture processing applications. These devices are chemically defined tissue culture media used to support the growth or maintenance of human tissue or cells in culture.
B. Principles of Operation and Technological Characteristics
Knockout™ SR
Knockout™ SR is a serum-free medium with a defined formulation that provides consistent growth conditions for human and mouse embryonic stem cell (ESC) and patient-specific induced pluripotent cell lines (iPSCs). Both ESC and iPSC grown in Knockout™ SR supplemented media are substantially less differentiated than those grown in fetal bovine serum (FBS) supplemented media. This media was introduced in 1998 and there are over 300 literature references to Knockout™ SR.
Knockout™ SR Xenofree
Knockout "M SR Xenofree is a serum-free and animal origin-free defined formulation that provides consistent growth conditions for human and mouse embryonic stem cell (ESC) and patient-specific induced pluripotent cell lines (iPSCs). All animal derived components have been replaced with human derived or synthetic components to yield a xenogeneic-free formulation. This media was developed and marketed in 2008.
C. Pre-clinical Testing
Performance Standards
Performance standards under Section 514 of the Federal Food, Drug, and Cosmetic Act have been established in Guidance Document "Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Tissue and Cell Culture Processing Applications: Final Guidance for Industry and FDA Reviewers," issued May 16, 2001. The specific assay tests and Life Technologies Corporation's equivalent tests that were conducted are identified in the table below.
{2}------------------------------------------------
K100616
313
Page 3 1 age 3
5 10(k) Summary - Life Technologies Knockout™ SR Medium and Knockout™ SR Xenofree Medium
| Special Control Objective | Life Technologies CorporationKnockoutTMSR Medium |
|---|---|
| Demonstrate lack of potentialtoxicity of materials in the media tocells or tissue and demonstratesupport of tissue and cell growth | ES Cell Morphology, relative plateefficiency, and relative type 1colonies |
| Demonstrate lack of endotoxin orpyrogen contamination | Limulus Ameobocyte (LAL) test (25USP Monograph <85>) |
| Validation of Aseptic Processing andSterility Assurance Level (SAL) | Determination of SAL to be ≥ $10^{-3}$ compliance withGMP requirements regarding aseptic processing |
| Demonstrates Chemical purity | Incoming Raw Material testing using USP, ACS,FCC, GIBCO, or Cell Culture requirements. |
Stability/Shelf Life
Based on analysis of product performance over time, Life Technologies Corporation has established a shelf life of 14-months for Knockout™ SR Medium and Knockout™ SR Xenofree Medium formulations, when stored between 2°C-8°C. Stability testing involved the assessment of these functional aspects of media, including demonstrating: ( ) that the pH continued to meet specifications; and (2) the media was not cytotoxic and supported the growth of mammalian cells. The pH was tested to demonstrate that the media was not chemically altered during its storage. In assessing cytoxicity/biocompatibility, Life Technologies Corporation demonstrated that the media functions in supporting the growth of mammalian cells and that the media does not become toxic to mammalian cells during storage. In addition, results from container/closure integrity testing have demonstrated that the container/closure system provides protection from microbial contamination.
D. Conclusion
Knockout™ SR Medium and Knockout™ SR Xenofree Medium and AIM-V® Medium are used for human ex vivo tissue and cell culture processing applications and have the same principles of operation, technological characteristics, efficacy (generic cellular growth and maintenance) and safety (consistency in chemical content and formulation, biocompatibility with cells, and purity). Their efficacy in supporting the survival, growth, development, and maintenance of human cells or tissue culture systems has been well established in scientific publications included in this submission. These products (Knockout 10) SR Medium and Knockout™ SR Xenofree Medium and AIM-V® Medium) are manufacturer in accordance with QSR requirements and are labeled as aseptically processed. Thus, Knockout™ SR Medium and Knockout™ SR Xenofree Medium are substantially equivalent to the legally marketed device intended for the human ex vivo tissue and cell culture processing applications.
{3}------------------------------------------------
Image /page/3/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of two main elements: the department's seal and the agency's symbol. The seal is a circular emblem with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. The symbol is a stylized depiction of an eagle, with three lines representing the bird's body and wings.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G60 Silver Spring, MD 20993-0002
Kelli L. Tanzella, Ph.D. Senior Manager, Americas Regulatory Affairs Life Technologies . 3175 Staley Road GRAND ISLAND NY 14072
MAY 2 0 2010
Re: K100616
Trade/Device Name: Knockout™ SR Medium
Knockout™ SR Xenofree Medium
Regulation Number: 21 CFR $876.5885
Regulation Name: Tissue culture media for human ex vivo tissue and cell culture processing applications
Regulatory Class: II Product Code: NDS Dated: March 4, 2010 Received: March 4, 2010
Dear Dr. Tanzella: .
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related
{4}------------------------------------------------
Page 2 -
adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Janine M. Morris
Acting Director, Division of Reproductive. Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
510(k) Number (if known):
Device Name: Knockout™ SR Medium Knockout™ SR Xenofree Medium
Indications for Use:
Knockout™ SR Medium and Knockout™ SR Xenofree Medium are liquid tissue culture medium products intended for human ex vivo tissue and cell culture processing applications.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHRE PAGE IF NEEDED)
Concurrence of CDRH, Office of Evaluation (ODE)
Prescription Use __
(Per 21 CFR 801.109)
OR
Over-The --Cour
(Optional Forma
(Division Sign-Off)
Division of Reproductive, Abdominal and
Radiological Devices
510(k) Number
Over-The --Counter Use (Optional Format 1-2-96)
§ 876.5885 Tissue culture media for human ex vivo tissue and cell culture processing applications.
(a)
Identification. Tissue culture media for human ex vivo tissue and cell culture processing applications consist of cell and tissue culture media and components that are composed of chemically defined components (e.g., amino acids, vitamins, inorganic salts) that are essential for the ex vivo development, survival, and maintenance of tissues and cells of human origin. The solutions are indicated for use in human ex vivo tissue and cell culture processing applications.(b)
Classification. Class II (special controls): FDA guidance document, “Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Processing Applications; Final Guidance for Industry and FDA Reviewers.”